Evidence map›Paper›PMID 37240047›Full record

ArticleInternational journal of molecular sciences2023

Activin A Limits VEGF-Induced Permeability via VE-PTP.

Basma Baccouche, Lina Lietuvninkas, Andrius Kazlauskas

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Basma BaccoucheDepartment of Ophthalmology & Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.
Lina LietuvninkasDepartment of Ophthalmology & Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.
Andrius KazlauskasDepartment of Ophthalmology & Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.
University of Illinois Chicago · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MCANANY, JAMES JASON · 1985 to 2025
$14.8M
Anti-VEGF-mediated barrier closureR01EY031350 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KAZLAUSKAS, ANDRIUS · 2020 to 2024
$1.9M
NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY031350NIH HHS EY031350
6 · The paper itself

Abstract

The clinical success of neutralizing vascular endothelial growth factor (VEGF) has unequivocally identified VEGF as a driver of retinal edema that underlies a variety of blinding conditions. VEGF is not the only input that is received and integrated by the endothelium. For instance, the permeability of blood vessels is also regulated by the large and ubiquitously expressed transforming growth factor beta (TGF-β) family. In this project, we tested the hypothesis that members of the TGF-β family influence the VEGF-mediated control of the endothelial cell barrier. To this end, we compared the effect of bone morphogenetic protein-9 (BMP-9), TGF-β1, and activin A on the VEGF-driven permeability of primary human retinal endothelial cells. While BMP-9 and TGF-β1 had no effect on VEGF-induced permeability, activin A limited the extent to which VEGF relaxed the barrier. This activin A effect was associated with the reduced activation of VEGFR2 and its downstream effectors and an increased expression of vascular endothelial tyrosine phosphatase (VE-PTP). Attenuating the expression or activity of VE-PTP overcame the effect of activin A. Taken together, these observations indicate that the TGF-β superfamily governed VEGF-mediated responsiveness in a ligand-specific manner. Furthermore, activin A suppressed the responsiveness of cells to VEGF, and the underlying mechanism involved the VE-PTP-mediated dephosphorylation of VEGFR2.

Indexed as

Endothelial CellsVascular Endothelial Growth Factor AActivinsEndothelium, VascularGrowth Differentiation Factor 2HumansProtein Tyrosine PhosphatasesTransforming Growth Factor betaTransforming Growth Factor beta1activin AActivinsGrowth Differentiation Factor 2Protein Tyrosine PhosphatasesTransforming Growth Factor betaTransforming Growth Factor beta1Vascular Endothelial Growth Factor AactivincrosstalkfollistatinpermeabilityVEGFVE-PTP

Identifiers

PMID37240047
PMCPMC10218593
OpenAlexW4376614809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.